Hanson & Doremus Investment Management Increases Holdings in GlaxoSmithKline plc (NYSE:GSK)

Share on StockTwits

Hanson & Doremus Investment Management boosted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,678 shares of the pharmaceutical company’s stock after purchasing an additional 596 shares during the period. Hanson & Doremus Investment Management’s holdings in GlaxoSmithKline were worth $1,677,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Marshall Wace North America L.P. purchased a new position in GlaxoSmithKline in the 1st quarter worth approximately $62,000. BlackRock Inc. increased its holdings in GlaxoSmithKline by 17.9% during the 2nd quarter. BlackRock Inc. now owns 1,527,105 shares of the pharmaceutical company’s stock worth $61,115,000 after purchasing an additional 232,266 shares during the period. NumerixS Investment Technologies Inc purchased a new position in GlaxoSmithKline during the 2nd quarter worth $268,000. Johnson Investment Counsel Inc. raised its position in GlaxoSmithKline by 8.5% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 18,890 shares of the pharmaceutical company’s stock valued at $755,000 after purchasing an additional 1,480 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in GlaxoSmithKline by 120.2% during the 2nd quarter. Private Advisor Group LLC now owns 135,966 shares of the pharmaceutical company’s stock valued at $5,314,000 after purchasing an additional 74,209 shares in the last quarter. Institutional investors own 11.27% of the company’s stock.

In other news, major shareholder Plc Glaxosmithkline acquired 357,142 shares of GlaxoSmithKline stock in a transaction dated Friday, October 18th. The stock was purchased at an average cost of $28.00 per share, for a total transaction of $9,999,976.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.

Several equities research analysts have weighed in on GSK shares. Barclays cut GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a report on Thursday. UBS Group raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating in a research report on Wednesday, November 27th. Svb Leerink initiated coverage on shares of GlaxoSmithKline in a research report on Monday, December 2nd. They issued an “outperform” rating on the stock. New Street Research raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Wednesday, October 16th. Finally, Leerink Swann began coverage on GlaxoSmithKline in a research note on Monday, December 2nd. They issued an “outperform” rating and a $53.00 price objective for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of $47.33.

Shares of NYSE:GSK traded down $0.38 during trading on Thursday, hitting $47.23. The stock had a trading volume of 1,422,156 shares, compared to its average volume of 1,723,374. GlaxoSmithKline plc has a 12-month low of $38.16 and a 12-month high of $47.79. The stock has a market capitalization of $117.33 billion, a price-to-earnings ratio of 14.94, a price-to-earnings-growth ratio of 3.12 and a beta of 0.68. The company has a quick ratio of 0.56, a current ratio of 0.82 and a debt-to-equity ratio of 1.38. The stock has a 50-day simple moving average of $46.39 and a two-hundred day simple moving average of $43.12.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.10. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. The firm had revenue of $11.57 billion during the quarter, compared to analysts’ expectations of $11.34 billion. As a group, sell-side analysts forecast that GlaxoSmithKline plc will post 3.25 earnings per share for the current year.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Stock Symbol

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.